Similarly, Güttlein’s work [13] also supports the utility of KRAS, NRAS and BRAF analysis in liquid biopsy from CRC patients with synchronous and metachronous metastases, finding an association between RAS/BRAF-mutated patients and a shorter OS. This evidence concerns the gene KRAS and colorectal carcinoma.